Santen Pharmaceutical Co (FRA:SZD) Total Operating Expense: €691 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:SZD Santen Pharmaceutical Co Ltd FRA:SZD
82 GF Score
Price €11.30
GF Value €8.99
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Total Operating Expense?

Santen Pharmaceutical Co FRA:SZD -1.74% 82 Total Operating Expense is €691 Mil as of Mar. 2026. GuruFocus rates FRA:SZD with a GF Score™ of 82/100 and a GF Value™ of €8.99. The stock has 6 warning signs investors should review.

Santen Pharmaceutical Co's Total Operating Expense for the three months ended in Mar. 2026 was €176 Mil. Santen Pharmaceutical Co's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €691 Mil.

Santen Pharmaceutical Co Total Operating Expense Related Terms

Santen Pharmaceutical Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Total Operating Expense Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 924.25 1,182.15 860.74 770.41 664.74

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 212.31 177.29 171.36 166.76 175.60
FRA:SZD
82GF Score
Santen Pharmaceutical Co Ltd FRA:SZD
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €691 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €691 Mil mean?
Santen Pharmaceutical Co (FRA:SZD) has a Total Operating Expense of €691 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Total Operating Expense too high?
Santen Pharmaceutical Co's current Total Operating Expense is €691 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Total Operating Expense compare to LLY and JNJ?
Santen Pharmaceutical Co's Total Operating Expense of €691 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Total Operating Expense is €691 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Santen Pharmaceutical Co (FRA:SZD) has a current Total Operating Expense of €691 Mil. The stock's GF Value™ is €8.99, compared to a current price of €11.30 — trading 25.7% above its estimated fair value. The current Total Operating Expense is €691 Mil. Santen Pharmaceutical Co's overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Santen Pharmaceutical Co (FRA:SZD), the current Total Operating Expense is €691 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (FRA:SZD) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of €11.30 is trading 25.7% above its estimated GF Value™ of €8.99.

Key valuation signals for FRA:SZD:

  • Total Operating Expense: €691 Mil
  • GF Value™: €8.99 vs. price of €11.30 (25.7% above fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the FRA:SZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
82GF Score

Get the complete analysis for FRA:SZD

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.30
Price
€8.99
GF Value